Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 8/20 | 1.00 |
| ▸ | TCF4 | P15884 | 7/20 | 1.00 |
| ▸ | CDH1 | P12830 | 2/20 | 1.00 |
| ▸ | APC | P25054 | 2/20 | 1.00 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cercosporin SCHEMBL15185706 | 0.83 | TCF4 (0.71) | CTNNB1TCF4CDH1APCTCF7L2 | |
| Cercosporin SCHEMBL29613349 | 0.83 | TCF4 (0.71) | CTNNB1TCF4CDH1APCTCF7L2 | |
| Cercosporin SCHEMBL498747 | 0.83 | TCF4 (0.71) | CTNNB1TCF4CDH1APCTCF7L2 | |
| Cercosporin SCHEMBL6305985 | 0.83 | TCF4 (0.71) | CTNNB1TCF4CDH1APCTCF7L2 | |
| Cercosporin SCHEMBL28102616 | 0.82 | TCF4 (0.70) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL29929662 | 0.81 | CTNNB1 (0.68) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL29711267 | 0.81 | CTNNB1 (0.68) | CTNNB1TCF4CDH1APCTCF7L2 | |
| Cercosporin SCHEMBL21175561 | 0.79 | TCF4 (0.65) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL22930428 | 0.78 | TCF4 (0.64) | CTNNB1TCF4CDH1APCTCF7L2 | |
| SCHEMBL31134383 | 0.69 | CTNNB1 (0.64) | CTNNB1TCF4CDH1APCTCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590297-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-03-31 | — | — | US | claimed |
| WO-2025262235-A1 | UNGULATE PLURIPOTENT STEM CELL CULTURE MEDIUM | MEAT TOMORROW APS (DK) | 2025-12-26 | — | — | WO | claimed |
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | Escend Pharmaceuticals, Inc. | 2024-10-17 | — | — | US | claimed |
| EP-3500686-B1 | METHODS FOR DETECTING CRANIOPHARYNGIOMA AND FOR SELECTING MEDICAMENTS AND PATIENTS FOR TREATMENT | QUEST DIAGNOSTICS INVEST LLC (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| US-20230272347-A1 | Differentiation Method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-08-31 | — | — | US | claimed |
| CN-116249520-A | Blocking replication of SARS-COV-2 and other pathogenic viruses using WNT/beta-catenin pathway inhibitors | 阿尔伯塔大学理事会 | 2023-06-09 | — | — | CN | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| US-11591572-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2023-02-28 | — | — | US | claimed |
| CN-115161257-A | Improved differentiation process | 荷兰皇家科学院 | 2022-10-11 | — | — | CN | claimed |
| CN-109477070-B | Improved differentiation process | 荷兰皇家科学院 | 2022-05-27 | — | — | CN | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| WO-2026106912-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743080-A2 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026090116-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090245-A1 | USE OF RAS INHIBITORS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20220091056-A1 | DIFFERENTIAL SCANNING MICROCALORIMETER DEVICE FOR DETECTING DISEASE AND MONITORING THERAPEUTIC EFFICACY | MONASELIDZE JAMLET (GE) | 2022-03-24 | — | — | US | disclosed |
| CN-114144516-A | Improved culture methods using integrin agonists | 荷兰皇家科学院 | 2022-03-04 | — | — | CN | disclosed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | disclosed |
| US-20220033904-A1 | Treating Atopic Dermatitis by Targeting the WNT Pathway | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272347-A1 | Differentiation Method | MYADM, EPCAM, MCL1 | CTNNB1 170/4885TCF4 86/4885CDH1 22/4885 |
| US-11591572-B2 | Differentiation method | MYADM, EPCAM, MCL1 | CTNNB1 170/4885TCF4 86/4885CDH1 22/4885 |
| US-20240342161-A1 | BISBENZYLISOQUINOLINES AS CONDITIONING AGENTS FOR IMMUNE THERAPY | NFATC1, CTNNB1, CAMK1D | CTNNB1 2/4885TCF4 301/4885CDH1 182/4885 |
| US-12590297-B2 | Differentiation method | WNT3A, SFRP1, WNT1 | CTNNB1 10/4885TCF4 28/4885CDH1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.